Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives $22.70 Consensus Target Price from Analysts

Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.70.

A number of brokerages have weighed in on SENS. Stifel Nicolaus set a $9.00 target price on shares of Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, March 3rd. Weiss Ratings assumed coverage on shares of Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “sell (d-)” rating on the stock. Finally, TD Cowen restated a “buy” rating on shares of Senseonics Holdings, Inc. Common Stock in a research report on Thursday, January 8th.

Senseonics Holdings, Inc. Common Stock Stock Up 2.9%

Shares of SENS stock opened at $6.49 on Friday. The firm has a market capitalization of $271.09 million, a P/E ratio of -3.84 and a beta of 0.90. Senseonics Holdings, Inc. Common Stock has a one year low of $5.25 and a one year high of $15.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.83 and a quick ratio of 4.55.

Insider Buying and Selling

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 17,500 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $5.73 per share, for a total transaction of $100,275.00. Following the completion of the acquisition, the director owned 119,731 shares in the company, valued at approximately $686,058.63. The trade was a 17.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Timothy T. Goodnow purchased 17,225 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $5.79 per share, with a total value of $99,732.75. Following the acquisition, the chief executive officer directly owned 651,243 shares of the company’s stock, valued at approximately $3,770,696.97. This trade represents a 2.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

A number of large investors have recently added to or reduced their stakes in the business. Aristides Capital LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock during the fourth quarter worth approximately $139,000. Virtu Financial LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at approximately $188,000. Quadrature Capital Ltd bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter worth approximately $321,000. Balyasny Asset Management L.P. bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter worth approximately $91,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $972,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.